尚荣医疗
(002551)
| 流通市值：21.27亿 | | | 总市值：29.42亿 |
| 流通股本：6.11亿 | | | 总股本：8.45亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 257,385,011.97 | 1,077,302,804.42 | 753,521,493.62 | 528,042,409.63 |
| 营业收入 | 257,385,011.97 | 1,077,302,804.42 | 753,521,493.62 | 528,042,409.63 |
| 二、营业总成本 | 263,960,900.4 | 1,153,967,258.09 | 804,037,290.47 | 554,274,104.42 |
| 营业成本 | 219,474,770.56 | 949,336,499.65 | 645,369,074.57 | 441,091,432.86 |
| 税金及附加 | 4,917,687.18 | 28,897,271.76 | 19,007,034.5 | 14,733,612.24 |
| 销售费用 | 3,755,946.87 | 19,329,051.1 | 12,783,009.78 | 8,725,117.65 |
| 管理费用 | 32,179,531.11 | 126,305,019.4 | 104,228,606.23 | 69,110,261.1 |
| 研发费用 | 8,703,056.4 | 41,564,415.36 | 26,438,636.82 | 20,173,329.07 |
| 财务费用 | -5,070,091.72 | -11,464,999.18 | -3,789,071.43 | 440,351.5 |
| 其中:利息费用 | 368,350.88 | 15,607,225.18 | 13,894,349.84 | 13,443,810.73 |
| 其中:利息收入 | 2,008,517.48 | 7,434,538.57 | 5,007,137.24 | 4,897,069.22 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,578,451.1 | 824,808.57 | -4,936,679.7 | -3,638,102.83 |
| 加:投资收益 | 2,416,667.32 | 15,284,664.17 | 10,204,894.94 | 7,087,511.07 |
| 资产处置收益 | 28,777.61 | 10,104,229.32 | 3,194.89 | 3,104.67 |
| 资产减值损失(新) | 6,217.72 | -22,038,371.43 | 10,364.86 | 10,253.94 |
| 信用减值损失(新) | 1,902,641.66 | -84,302,732.78 | 10,654,888.28 | 17,312,590.11 |
| 其他收益 | 970,836.13 | 6,397,902.3 | 2,967,763.12 | 1,733,681.91 |
| 四、营业利润 | 327,703.11 | -150,393,953.52 | -31,611,370.46 | -3,722,655.92 |
| 加:营业外收入 | 36,788.19 | 5,386,507.31 | 2,112,135 | 1,095,560.09 |
| 减:营业外支出 | 84,900.31 | 12,573,434.53 | 569,793.26 | 393,715.98 |
| 五、利润总额 | 279,590.99 | -157,580,880.74 | -30,069,028.72 | -3,020,811.81 |
| 减:所得税费用 | 1,513,928.31 | -11,372,863.72 | 4,591,622.42 | 1,499,341.75 |
| 六、净利润 | -1,234,337.32 | -146,208,017.02 | -34,660,651.14 | -4,520,153.56 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -1,234,337.32 | -146,208,017.02 | -34,660,651.14 | -4,520,153.56 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -1,806,254.42 | -139,581,671.9 | -35,125,254.33 | -7,758,226.19 |
| 少数股东损益 | 571,917.1 | -6,626,345.12 | 464,603.19 | 3,238,072.63 |
| 扣除非经常损益后的净利润 | -5,508,541.18 | -162,768,657.06 | -42,325,482.07 | -12,518,689.29 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0 | -0.17 | -0.04 | -0.01 |
| (二)稀释每股收益 | 0 | -0.16 | -0.04 | -0.01 |
| 八、其他综合收益 | -3,968,922.52 | -10,430,756.03 | -7,319,782.48 | -4,231,991.86 |
| 归属于母公司股东的其他综合收益 | -5,768,543.29 | -11,636,511.2 | -8,371,435.31 | -5,302,067.94 |
| 九、综合收益总额 | -5,203,259.84 | -156,638,773.05 | -41,980,433.62 | -8,752,145.42 |
| 归属于母公司股东的综合收益总额 | -7,574,797.71 | -151,218,183.1 | -43,496,689.64 | -13,060,294.13 |
| 归属于少数股东的综合收益总额 | 2,371,537.87 | -5,420,589.95 | 1,516,256.02 | 4,308,148.71 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-28 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |